Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.
Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA.
Knisely A, et al. Among authors: serrano ag.
Clin Cancer Res. 2025 Oct 1;31(19):4122-4135. doi: 10.1158/1078-0432.CCR-25-0512.
Clin Cancer Res. 2025.
PMID: 40748258
Free PMC article.